Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Charles S. Fuchs appointed President, Research & Development effective August 10, 2026.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Charles S. Fuchs appointed President, Research & Development effective August 10, 2026
- Oncology veteran brings Roche, Genentech, Yale Cancer Center, and Tubulis leadership experience
- Compensation includes $570,000 base salary, 45% target bonus, and options for 1,300,000 shares
- Equity options vest over four years, increasing potential dilution while aligning retention incentives
- New inducement plan reserves 6,200,000 shares without stockholder approval under Nasdaq rules
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.